Nanobiotix (NBTX) Receivables - Net (2019 - 2025)

Nanobiotix (NBTX) has 6 years of Receivables - Net data on file, last reported at $2.5 million in Q4 2025.

• In Q4 2025, Receivables - Net fell 22.44% year-over-year to $2.5 million; the TTM figure through Dec 2025 stood at $2.5 million (down 22.44% YoY), while the FY2025 annual figure was $2.4 million, down 25.68% from the prior year.
• Receivables - Net slipped to $2.5 million in Q4 2025, from $3.2 million in the prior quarter.
• Across five years, Receivables - Net topped out at $3.2 million in Q4 2024 and bottomed at $103045.0 in Q4 2022.
• A 4-year average of $1.7 million and a median of $1.7 million in 2023 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2023 — Receivables - Net soared 839.73% — and 2025, when it declined 22.44%.
• Year by year, Receivables - Net stood at $103045.0 in 2022, then soared by 839.73% to $968345.9 in 2023, then jumped by 231.06% to $3.2 million in 2024, then retreated by 22.44% to $2.5 million in 2025.
• The last three Receivables - Net figures came in at $2.5 million (Q4 2025), $3.2 million (Q4 2024), and $968345.9 (Q4 2023), per Business Quant data.

Peer Comparison